RxDoctor Payments Data

Julio Diaz, MD

Internal Medicine · Linden, NJNPI 1831192129

Payments from drug & device makers

$2,592in general payments, 2019–2025

Across 104 payments — averaging $24.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Tosoh Bioscience, Inc.$758
  • Lilly USA, LLC$352
  • Novo Nordisk$255
  • GSK$250
  • AstraZeneca$219
  • Merck$161
  • plus $597 from 13 others

What the payments were for

  • Food & beverage$1,83471%
  • Gifts$75829%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,592 in reported general payments places this provider in the 80th percentile of 4,032 internal medicine providers in New Jersey.

See all internal medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$335,016
Medicare patients
587
Services billed
10,770

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol164$140,824
MounjaroTirzepatide54$67,295
EliquisApixaban44$35,765
TrulicityDulaglutide19$32,934
JardianceEmpagliflozin51$30,825
JanuviaSitagliptin Phosphate20$21,483
ArexvyRsvpref3 Antigen/As01e/Pf67$20,206
JanumetSitagliptin Phos/Metformin Hcl13$14,411
XareltoRivaroxaban14$11,658
Atorvastatin Calcium623$10,103
ShingrixVaricella-Zoster Ge/As01b/Pf35$7,679
JentaduetoLinagliptin/Metformin Hcl13$6,783
TradjentaLinagliptin12$6,297
Losartan Potassium296$3,426
Metformin Hcl324$2,556

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$219$140,824164 claims
Lilly USA, LLCMounjaro, Trulicity$352$100,22973 claims
MerckJanuvia, Janumet$161$35,89433 claims
PfizerEliquis$126$35,76544 claims
GSKArexvy, Shingrix$250$27,885102 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,032 internal medicine providers in New Jersey.

Other internal medicine in Linden

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →